                         SEQUENCE LISTING

<110>  NOGRA PHARMA LIMITED
 
<120>  COMPOSITIONS OF SMAD7 ANTISENSE OLIGONUCLEOTIDE AND METHODS OF 
       USING THE SAME

<130>  GIU-061WO

<150>  63/015,120
<151>  2020-04-24

<150>  63/030,818
<151>  2020-05-27

<150>  63/135,283
<151>  2021-01-08

<160>  6     

<170>  PatentIn version 3.5

<210>  1
<211>  21
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Description of Artificial Sequence: Synthetic oligonucleotide


<220>
<221>  modified_base
<222>  (3)..(3)
<223>  5-methyl-2'-deoxycytidine

<220>
<221>  modified_base
<222>  (16)..(16)
<223>  5-methyl-2'-deoxycytidine

<400>  1
gtcgcccctt ctccccgcag c                                                 21


<210>  2
<211>  21
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Description of Artificial Sequence: Synthetic oligonucleotide


<220>
<221>  modified_base
<222>  (3)..(3)
<223>  5-methyl-2'-deoxycytidine

<220>
<221>  modified_base
<222>  (16)..(16)
<223>  5-methyl-2'-deoxycytidine

<400>  2
gtcgcccctt ctctccgcag c                                                 21


<210>  3
<211>  20
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Description of Artificial Sequence: Synthetic oligonucleotide


<220>
<223>  See specification as filed for detailed description of 
       substitutions and preferred embodiments

<220>
<221>  modified_base
<222>  (3)..(3)
<223>  Nitrogenous base cytosine, 5-methylcytosine or 
       2'-O-methylcytosine

<220>
<221>  modified_base
<222>  (4)..(4)
<223>  Nitrogenous base guanine, 5-methylguanine or 2'-O-methylguanine

<220>
<221>  modified_base
<222>  (16)..(16)
<223>  Nitrogenous base cytosine, 5-methylcytosine or 
       2'-O-methylcytosine

<220>
<221>  modified_base
<222>  (17)..(17)
<223>  Nitrogenous base guanine, 5-methylguanine or 2'-O-methylguanine

<400>  3
gtcgcccctt ctccccgcag                                                   20


<210>  4
<211>  20
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Description of Artificial Sequence: Synthetic oligonucleotide


<220>
<221>  modified_base
<222>  (3)..(3)
<223>  5-methyl-2'-deoxycytidine

<220>
<221>  modified_base
<222>  (16)..(16)
<223>  5-methyl-2'-deoxycytidine

<400>  4
gtcgcccctt ctccccgcag                                                   20


<210>  5
<211>  21
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Description of Artificial Sequence: Synthetic oligonucleotide


<220>
<223>  See specification as filed for detailed description of 
       substitutions and preferred embodiments

<220>
<221>  modified_base
<222>  (3)..(3)
<223>  5-methyl-2'-deoxycytidine

<220>
<221>  modified_base
<222>  (16)..(16)
<223>  5-methyl-2'-deoxycytidine

<220>
<221>  modified_base
<222>  (17)..(17)
<223>  Nitrogenous base guanine, 5-methylguanine or 2'-O-methylguanine

<400>  5
gtcgcccctt ctccccgcag c                                                 21


<210>  6
<211>  21
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Description of Artificial Sequence: Synthetic oligonucleotide


<220>
<223>  See specification as filed for detailed description of 
       substitutions and preferred embodiments

<220>
<221>  modified_base
<222>  (3)..(3)
<223>  5-methyl-2'-deoxycytidine

<220>
<221>  modified_base
<222>  (16)..(16)
<223>  5-methyl-2'-deoxycytidine

<220>
<221>  modified_base
<222>  (17)..(17)
<223>  Nitrogenous base guanine, 5-methylguanine or 2'-O-methylguanine

<400>  6
gtcgcccctt ctctccgcag c                                                 21


